LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t.
- Who it may be relevant to
- Registry conditions: Lung, Lung Cancer, Cancer, NSCLC. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics
Overview
This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.
Interventions
- Other Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t
Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.
Primary outcome measures
- Area Under the Curve [Time frame: 3 years]
Secondary outcome measures (1)
- Differentially Expressed Proteins [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Signing of the informed consent form;
- Male or female, aged 18-75 years;
- Patients with lung nodules confirmed by CT examination;
- Good preoperative pulmonary function cooperation and complete reporting;
- Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
- The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.
Exclusion criteria
- Poor preoperative pulmonary function cooperation or missing reports;
- Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
- The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
- Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
- Coexisting with other severe functional impairments;
- Patients with obstructive lesions such as airway or esophageal stenosis;
(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- the First Affiliated of Guangzhou Medical University — Guangzhou
Identifiers
NCT: NCT06778512 · LcProt · ES-2924-051-02